Expanding the Investor Presentation

July 10, 2026

Pharmaceutical Manufacturing Strategy

July 15, 2026

Development timline

Strengthening the Scientific Foundation

The scientific rationale supporting THCA Therapeutics was further expanded through literature review and evidence mapping. Mechanistic pathways involving PPARγ activation, NF-κB inhibition, oxidative stress reduction, neuroprotection, and immune modulation were incorporated into the company’s research framework.